home | publications


1. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M:
JNCI, 95:1376-83, 2003.

2. Diagnostic Potential Of Serum Proteomic Patterns In Prostate Cancer.
Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B-L, McLeod DG, Moul JW and Srivastava S:
J. Urol., 170:442-6, 2003.

3. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.
Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T.
Urol Oncol. 21:447-55,2003.

4. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.
Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S.
Cancer Res. 63: 4299-304, 2003.

5. Using the percentage of biopsy cores positive for cancer, pre-treatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms.
Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Urology, 61:589-95,2003.

6. Predictors of extracapsular extension and positive margins in African-American and Caucasian men.
Paquette EL, Connelly RR, Sun L, Paquette LR, Moul JW:
Urologic Oncology, 21:33-8, 2003.

7. Pretreatment total testosterone level predicts pathologic stage in radical prostatectomy patients with localized prostate cancer.
Massengill JC, Sun, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T:
J Urol, 169:1670-5, 2003.

8. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG, Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL:
Int J Radiat Oncol Biol Phys. 55:964-9, 2003.

9. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.
Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S.
Clin Cancer Res. 9(7):2545-50, 2003.

10. Early prostate cancer: prevention, treatment modalities, and quality of life issues.
Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulman CC.
Eur Urol. 44:283-93,2003.

11. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V.
Eur Urol. 43:12-27, 2003.

12. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.
J Clin Oncol. 21:2163-72, 2003.

13. A novel neoplastic primary tumor-derived human prostate epithelial cell line.
Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS.
Int J Oncol. 22:1311-7, 2003.

14. Methylation of TFPI-2 gene is not the sole cause of its silencing.
Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW, Phillips B.
Int J Oncol. 22:843-8, 2003.

15. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA.
Oncol Rep. 10:223-8, 2003.

16. Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo.
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, Ruzinski JT, Rhim JS, Martin TR, Goodman RB.
Immunol. 170:5244-51, 2003.

17. Generation of immortal human prostate cell lines for the study of prostate cancer.
Rhim JS.
Methods Mol Med. 81:69-77, 2003.

18. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW.
Urology. 61:607-11, 2003.

19. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer Prostate Cancer.
Riffenburgh RH, Amling CL.
Prostatic Dis. 6:39-44, 2003.

20. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH Database.
Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK;
SEARCH Database Study Group.
Urology. 61:736-41, 2003.


21. SEARCH Database Study Group Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK;
Urology. 61:742-7, 2003.

22. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T:
J Urol, 169:1670-5, 2003.

23. Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover.
Elliot SJ, Zorn BH, McLeod DG, Moul JW, Nyberg L, Striker LJ, Striker GE:
Prostate Cancer Prostatic Dis., 6:138-42.

24. The current art of prostate needle biopsy.
Donahue T, Moul J:
Contemporary Urology, 15:72-81, 2003.

25. The role of hormonal therapy for PSA-only recurrence of PCA after local therapy.
Moul JW, Zlotta AR:
Contemporary Urology, 15:31-36, 2003.

26. Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era.
C Carter, T Donahue, L Sun, H Wu, D. McLeod, C Amling, R Lance,
J Foley, W Sexton, L Kusuda, A Chung, D Soderdahl, S Jackman, and JW. Moul
Jour Clin Oncology, Vol 21, No 21 (November 1), 2003: pp 4001-4008.

27. Diagnostic Potential of Prostate-specific Antigen Expressing Epithelial Cells in Blood of Prostate Cancer Patients.
Chun-Ling Gao, Sudhir K. Rawal, Leon Sun, Amina Ali, Roger R. Connelly, Lionel L. Bañez, Isabell A. Sesterhenn, David G. Mcleod, Judd W. Moul, and Shiv Srivastava
Clinical Cancer Research, Vol. 9, 2545–2550, July 2003.

28. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
GL Griewe, RC Dean, W Zhang, D Young, IA Sesterhenn,
N Shanmugam, DG McLeod1, JW Moul, S Srivastava
Prostate Cancer and Prostatic Diseases (2003) 6, 281–285.

29. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.
JW. Moul, JE Fowler, Jr.
Urology 62 (Supplement 6A), December 22, 2003.